Medical News

RSS

Brain abnormalities associated with schizophrenia risk are detectable in babies, find researchers

Schizophrenia is a debilitating mental disorder affecting one in 100 people worldwide. Most cases aren't detected until a person starts experiencing symptoms like delusions and hallucinations as a teenager or adult. By that time, the disease has often progressed so far that it can be difficult to treat.

22 Jun 2010

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene-IV, which is marketed by Roche Laboratories, Inc.

22 Jun 2010

Lack of tracking of medical devices' performance raises questions about safety and efficacy

"Amid the booming use of artificial joints in the United States, the breakup between Dr. Berger and Zimmer highlights what experts say is a troubling situation for patients and doctors: when disputes arise about orthopedic implant safety, there are no independent referees or sources of information because no one tracks the performance of the devices.

22 Jun 2010

MU researcher explores importance of spirituality in youth development

Few studies have examined the differences between spirituality and religion in adolescents. Now, a University of Missouri researcher is exploring these differences by determining how youth define and practice spirituality separate from religion. Defining spirituality can help reveal its impact on adolescent development. Initial findings reveal that youth define spirituality in terms of positive behaviors, feelings and relationships.

22 Jun 2010

Star Scientific seeks FDA approval of Stonewall-BDL as "modified risk tobacco product"

Star Scientific, Inc. announced that on Friday, June 18 the company filed an application with the Food & Drug Administration for approval to market Stonewall-BDL™ as a "modified risk tobacco product" under the Family Smoking Prevention and Tobacco Control Act of 2009. This is Star's second such application to the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.

22 Jun 2010

Standard X-rays can help physicians diagnose laparoscopic adjustable gastric band slippage: Study

Standard radiography (X-rays) can help physicians diagnose laparoscopic adjustable gastric band slippage, a known complication of adjustable gastric banding surgery, according to a study published in the July issue of the American Journal of Roentgenology. Adjustable gastric banding surgery is a widely used bariatric surgical procedure to induce weight loss in morbidly obese individuals.

22 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

Ipsen today announced top line results of GuidAge®, the longest (5 years) and largest (2,854 subjects) European study in the prevention of Alzheimer's Dementia (AD). This trial was conducted according to the most stringent international standards. The aim of this study was to assess the efficacy of a 5-year treatment with EGb 761® in the prevention of Alzheimer's Dementia in a population of elderly aged 70 or more, with memory complaint spontaneously expressed to their family physician and who lived at home at the inclusion in the study.

22 Jun 2010

Protesters ask U.S. to boost funding for Global Fund, HIV/AIDS programs in Africa

Thousands of protesters in Pretoria, South Africa, Thursday "demand[ed] the U.S. increase its AIDS funding for Africa," the Associated Press reports (Naki, 6/17). The protesters delivered a letter to the consulate saying the U.S. is "cutting funding to the Global Fund to Fight AIDS, Tuberculosis and Malaria," which health advocates believe could lead "other countries to follow suit and reduce funding for the fight against HIV," Agence France-Presse writes (6/17).

22 Jun 2010

Extenders bill in limbo, placing COBRA subsidy and Medicaid enhanced funding in even deeper jeopardy

Efforts to renew the COBRA subsidy extension to help workers who have been recently laid off afford to keep their former employer's health insurance remains in limbo as lawmakers work at a measured pace to extend unemployment benefits and a tax package.

22 Jun 2010

FDA grants approval for newest version of OnGuard Chest X-ray CAD technology

Riverain Medical announced today that the U.S. Food and Drug Administration has granted approval for the newest version of the OnGuard Chest X-ray Computer-Aided Detection technology. OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. This improved performance demonstrates a 73% reduction in false positive marks and 50% higher relative sensitivity compared to the original product.

22 Jun 2010

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Hunger hormone ghrelin heightens the appeal of high-calorie foods over low-calorie foods: Study

The "hunger" hormone ghrelin, which acts in the brain to stimulate hunger and increase food intake, heightens the appeal of high-calorie foods over low-calorie foods, according to a study that will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Discoveries in study and manipulation of human ES cells win first prize in research competition

World-recognized discoveries in the study and manipulation of human embryonic stem cells have won first prize in a prestigious applied research competition for a Hebrew University of Jerusalem researcher.

22 Jun 2010

WHO issues comprehensive recommendations on children's medicines

The WHO on Friday issued "its first-ever guidance on how to use more than 240 essential medicines for children under 13," the Associated Press reports. "The data provide information on use, dosage and side effects of medicines as well as warnings about which children should not take them" and possible complications from interactions from drugs taken together, according to the WHO, the news service reports (6/19).

22 Jun 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

USAID Administrator shares vision for agency reform

During a speech at the National Press Club on Friday, USAID Administrator Rajiv spoke about ongoing efforts to reform the agency he oversees, noting the importance of improving development strategies targeting women, among other things, All Headline News reports (6/20).

22 Jun 2010

Health leaders formally launch new strategy for polio eradication

Health leaders from around the world gathered on Friday to formally launch a new strategy for eradicating polio, Newsweek's "The Human Condition" blog reports in a post examining the challenges and successes health advocates face in attempting to wipe the virus out completely (Carmichael, 6/18).

22 Jun 2010

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

22 Jun 2010

Medical News

Brain abnormalities associated with schizophrenia risk are detectable in babies, find researchers

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

Lack of tracking of medical devices' performance raises questions about safety and efficacy

MU researcher explores importance of spirituality in youth development

Star Scientific seeks FDA approval of Stonewall-BDL as "modified risk tobacco product"

Standard X-rays can help physicians diagnose laparoscopic adjustable gastric band slippage: Study

Women with PCOS may be more vulnerable to BPA exposure: Study

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

Protesters ask U.S. to boost funding for Global Fund, HIV/AIDS programs in Africa

Extenders bill in limbo, placing COBRA subsidy and Medicaid enhanced funding in even deeper jeopardy

FDA grants approval for newest version of OnGuard Chest X-ray CAD technology

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Hunger hormone ghrelin heightens the appeal of high-calorie foods over low-calorie foods: Study

Discoveries in study and manipulation of human ES cells win first prize in research competition

WHO issues comprehensive recommendations on children's medicines

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

USAID Administrator shares vision for agency reform

Health leaders formally launch new strategy for polio eradication

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News